NK cells in pancreatic cancer demonstrate impaired cytotoxicity and a regulatory IL-10 phenotype

References

• Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study. Lancet. 2015;385(9974):1206–13. doi:10.1016/S0140-6736(14)61396-9.
   PubMed Web of Science ®Google Scholar
• Ducreux M, Committee Obot EG, Cuhna AS, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2015;26(suppl_5):v56–v68. doi:10.1093/annonc/mdv295.
   PubMed Web of Science ®Google Scholar
• Warshaw AL, Castillo CF-D. Pancreatic Carcinoma. New England J Med. 1992;326(7):455–465. doi:10.1056/nejm199202133260706.
   PubMed Web of Science ®Google Scholar
• Bates SE. Pancreatic Cancer: challenge and Inspiration. Clin Cancer Res. 2017;23(7): 1628–28. doi:10.1158/1078-0432.Ccr-16-2069.
   Web of Science ®Google Scholar
• Kenner BJ, Chari ST, Maitra A, Srivastava S, Cleeter DF, Go VLW, Rothschild LJ, Goldberg AE. Early Detection of Pancreatic Cancer-a Defined Future Using Lessons From Other Cancers: A White Paper. Pancreas. 2016;45(8):1073–1079. doi:10.1097/MPA.0000000000000701.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer. New England J Med. 2012;366(26):2455–2465. doi:10.1056/NEJMoa1200694.
   PubMed Web of Science ®Google Scholar
• Merika EE, Syrigos KN, Saif MW. Desmoplasia in Pancreatic Cancer. Can We Fight It? Gastroenterol Res Pract. 2012;2012:10. doi:10.1155/2012/781765.
   Web of Science ®Google Scholar
• Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor Cell Interactions with the Extracellular Matrix During Invasion and Metastasis. Annu Rev Cell Biol. 1993;9(1):541–573. doi:10.1146/annurev.cb.09.110193.002545.
   PubMedGoogle Scholar
• Gaggioli C, Hooper S, Hidalgo-Carcedo C, Grosse R, Marshall JF, Harrington K, Sahai E. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol. 2007;9(12):1392–1400. doi:10.1038/ncb1658.
   PubMed Web of Science ®Google Scholar
• Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion. Cell. 2005;121(3):335–348. doi:10.1016/j.cell.2005.02.034.
   PubMed Web of Science ®Google Scholar
• von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Jöhnk C, Henne-Bruns D, Kremer B, Kalthoff H. Systemic and Local Immunosuppression in Pancreatic Cancer Patients. Clin Cancer Res. 2001;7(3):925s–32s.
   PubMed Web of Science ®Google Scholar
• Wörmann SM, Diakopoulos KN, Lesina M, Algül H. The immune network in pancreatic cancer development and progression. Oncogene. 2014;33(23):2956–2967. doi:10.1038/onc.2013.257.
   PubMed Web of Science ®Google Scholar
• Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D, Robecchi A, Emanuelli G, Rodeck U. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol. 1999;155(2):537–547. doi:10.1016/s0002-9440(10)65149-8.
   PubMed Web of Science ®Google Scholar
• Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y, et al. CD8+ Tumor-Infiltrating Lymphocytes Together with CD4+ Tumor-Infiltrating Lymphocytes and Dendritic Cells Improve the Prognosis of Patients with Pancreatic Adenocarcinoma. Pancreas. 2004;28(1):e26–e31. doi:10.1097/00006676-200401000-00023.
   PubMed Web of Science ®Google Scholar
• Protti MP, De Monte L. Immune infiltrates as predictive markers of survival in pancreatic cancer patients. Front Physiol. 2013;4:210. doi:10.3389/fphys.2013.00210.
   PubMed Web of Science ®Google Scholar
• Nejati R, Goldstein JB, Halperin DM, Wang H, Hejazi N, Rashid A, Katz MH, Lee JE, Fleming JB, Rodriguez-Canales J, et al. Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy. Pancreas. 2017;46(9):1180–1187. doi:10.1097/mpa.0000000000000914.
   PubMed Web of Science ®Google Scholar
• Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, Hiraoka N. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer. 2013;108(4):914–923. [published Online First: 2013/02/05]. doi:10.1038/bjc.2013.32.
   PubMed Web of Science ®Google Scholar
• Meng Q, Liu Z, Rangelova E, Poiret T, Ambati A, Rane L, Xie S, Verbeke C, Dodoo E, Del Chiaro M, et al. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer. J Immunother. 2016;39(2):81–89. doi:10.1097/cji.0000000000000111.
   PubMed Web of Science ®Google Scholar
• Lim SA, Kim J, Jeon S, Shin MH, Kwon J, Kim T-J, Im K, Han Y, Kwon W, Kim S-W, et al. Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients. Front Immunol. 2019;10:496. doi:10.3389/fimmu.2019.00496.
   PubMed Web of Science ®Google Scholar
• Hoshikawa M, Aoki T, Matsushita H, Karasaki T, Hosoi A, Odaira K, Fujieda N, Kobayashi Y, Kambara K, Ohara O, et al. NK cell and IFN signatures are positive prognostic biomarkers for resectable pancreatic cancer. Biochem Biophys Res Commun. 2018;495(2):2058–2065. doi:10.1016/j.bbrc.2017.12.083.
   PubMed Web of Science ®Google Scholar
• Davis M, Conlon K, Bohac GC, Barcenas J, Leslie W, Watkins L, Lamzabi I, Deng Y, Li Y, Plate JMD, et al. Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas. J Immunoth. (Hagerstown, Md: 1997). 2012;35(8):629–640. [published Online First: 2012/09/22]. doi:10.1097/CJI.0b013e31826c8a4f.
   PubMed Web of Science ®Google Scholar
• Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000;356(9244):1795–1799. doi:10.1016/S0140-6736(00)03231-1.
   PubMed Web of Science ®Google Scholar
• Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 2016;17:1025. doi:10.1038/ni.3518.
   PubMed Web of Science ®Google Scholar
• Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2015;16:7. doi:10.1038/nrc.2015.5.
   Web of Science ®Google Scholar
• Hicklin DJ, Marincola FM, Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today. 1999;5(4):178–186. doi:10.1016/S1357-4310(99)01451-3.
   PubMedGoogle Scholar
• Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419(6908):734–738. doi:10.1038/nature01112.
   PubMed Web of Science ®Google Scholar
• Parry HM, Stevens T, Oldreive C, Zadran B, McSkeane T, Rudzki Z, Paneesha S, Chadwick C, Stankovic T, Pratt G, et al. NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma. Oncotarget. 2016;7(42):68513–68526. doi:10.18632/oncotarget.12097.
   PubMedGoogle Scholar
• Lanier LL. NKG2D Receptor and Its Ligands in Host Defense. Cancer Immunol Res. 2015;3(6):575–582. doi:10.1158/2326-6066.CIR-15-0098.
   PubMed Web of Science ®Google Scholar
• Oberschmidt O, Kloess S, Koehl U. Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an “Off-the-Shelf Immunotherapy” for Improvement in Cancer Treatment. Front Immunol. 2017;8(654). doi:10.3389/fimmu.2017.00654.
   Google Scholar
• Michel T, Poli A, Cuapio A, Briquemont B, Iserentant G, Ollert M, Zimmer J. Human CD56 bright NK Cells: an Update. J Immunol. 2016;196(7):2923–2931. doi:10.4049/jimmunol.1502570.
   PubMed Web of Science ®Google Scholar
• Nielsen C, White M, Goodier M, Riley EM. Functional Significance of CD57 Expression on Human NK Cells and Relevance to Disease. Front Immunol. 2013;4:422. doi:10.3389/fimmu.2013.00422.
   PubMed Web of Science ®Google Scholar
• Poli A, Michel T, Thérésine M, Andrès E, Hentges F, Zimmer J. CD56 bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126(4):458–465. doi:10.1111/j.1365-2567.2008.03027.x.
   PubMed Web of Science ®Google Scholar
• Moretta L. Dissecting CD56dim human NK cells. Blood. 2010;116(19):3689–3691. doi:10.1182/blood-2010-09-303057.
   PubMed Web of Science ®Google Scholar
• Abel AM, Yang C, Thakar MS, Malarkannan S. Natural Killer Cells: development, Maturation, and Clinical Utilization. Front Immunol. 2018;9:1869. doi:10.3389/fimmu.2018.01869.
   PubMed Web of Science ®Google Scholar
• Amand M, Iserentant G, Poli A, Sleiman M, Fievez V, Sanchez IP, Sauvageot N, Michel T, Aouali N, Janji B, et al. Human CD56dimCD16dim Cells As an Individualized Natural Killer Cell Subset. Front Immunol. 2017;8:699. doi:10.3389/fimmu.2017.00699.
   PubMed Web of Science ®Google Scholar
• Jun E, Song AY, Choi J-W, Lee HH, Kim M-Y, Ko D-H, Kang HJ, Kim SW, Bryceson Y, Kim SC, et al. Progressive Impairment of NK Cell Cytotoxic Degranulation Is Associated With TGF-β1 Deregulation and Disease Progression in Pancreatic Cancer. Front Immunol. 2019;10:1354. doi:10.3389/fimmu.2019.01354.
   PubMed Web of Science ®Google Scholar
• Peng Y-P, Zhu Y, Zhang -J-J, Xu Z-K, Qian Z-Y, Dai -C-C, Jiang K-R, Wu J-L, Gao W-T, Li Q, et al. Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer. J Transl Med. 2013;11(1):262. doi:10.1186/1479-5876-11-262.
   PubMed Web of Science ®Google Scholar
• Funa K, Nilsson B, Jacobsson G, Alm GV. Decreased natural killer cell activity and interferon production by leucocytes in patients with adenocarcinoma of the pancreas. Br J Cancer. 1984;50(2):231–233. doi:10.1038/bjc.1984.168.
   PubMed Web of Science ®Google Scholar
• Peng Y-P, Zhang -J-J, Liang W-B, Tu M, Lu Z-P, Wei J-S, Jiang K-R, Gao W-T, Wu J-L, Xu Z-K, et al. Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction. BMC Cancer. 2014;14(1):738. doi:10.1186/1471-2407-14-738.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, Wang Z, Wu Q, Peng H, Wei H, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19(7):723–732. doi:10.1038/s41590-018-0132-0.
   PubMed Web of Science ®Google Scholar
• Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, Rautela J, Straube J, Waddell N, Blake SJ, et al. Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat Immunol. 2017;18(9):1004–1015. doi:10.1038/ni.3800.
   PubMed Web of Science ®Google Scholar
• Duan X, Deng L, Chen X, Lu Y, Zhang Q, Zhang K, Hu Y, Zeng J, Sun W. Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer. Med Oncol. 2011;28(2):466–474. doi:10.1007/s12032-010-9480-9.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhu -X-X, Xu H, Fang H-Z, Zhao J-Q. Expression and prognostic significance of unique ULBPs in pancreatic cancer. Onco Targets Ther. 2016;9:5271–5279. doi:10.2147/OTT.S107771.
   PubMed Web of Science ®Google Scholar
• Chen J, Xu H, Zhu -X-X. Abnormal expression levels of sMICA and NKG2D are correlated with poor prognosis in pancreatic cancer. Ther Clin Risk Manag. 2015;12:11–18. doi:10.2147/TCRM.S96869.
   PubMed Web of Science ®Google Scholar
• Märten A, von Lilienfeld-toal M, Büchler MW, Schmidt J. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing γδ T cell cytotoxicity. Inter J Can. 2006;119(10):2359–2365. doi:10.1002/ijc.22186.
   PubMed Web of Science ®Google Scholar
• Chan YLT, Zuo J, Inman C, Croft W, Begum J, Croudace J, Kinsella F, Maggs L, Nagra S, Nunnick J, et al. NK cells produce high levels of IL-10 early after allogeneic stem cell transplantation and suppress development of acute GVHD. Eur J Immunol. 2018;48(2):316–329. [published Online First: 2017/10/27]. doi:10.1002/eji.201747134.
   PubMed Web of Science ®Google Scholar
• Tarrio ML, Lee S-H, Fragoso MF, Sun H-W, Kanno Y, O’Shea JJ, Biron CA. Proliferation Conditions Promote Intrinsic Changes in NK Cells for an IL-10 Response. J Immunol. 2014;193(1):354–363. doi:10.4049/jimmunol.1302999.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Yang M, Sun X, Chen X, Ma M, Yin X, Qian S, Zhang Z, Fu Y, Liu J, et al. IL-10+ NK and TGF-β+ NK cells play negative regulatory roles in HIV infection. BMC Infect Dis. 2018;18(1):80. doi:10.1186/s12879-018-2991-2.
   PubMed Web of Science ®Google Scholar
• Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA. Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood. 2001;97(10):3146–3151. doi:10.1182/blood.V97.10.3146.
   PubMed Web of Science ®Google Scholar
• De Maria A, Bozzano F, Cantoni C, Moretta L. Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci U S A. 2011;108(2):728–732. [published Online First: 12/27]. doi:10.1073/pnas.1012356108.
   PubMed Web of Science ®Google Scholar
• Curd LM, Favors SE, Gregg RK. Pro-tumour activity of interleukin-22 in HPAFII human pancreatic cancer cells. Clin Exp Immunol. 2012;168(2):192–199. doi:10.1111/j.1365-2249.2012.04570.x.
   PubMed Web of Science ®Google Scholar
• Brooks J, Fleischmann-Mundt B, Woller N, Niemann J, Ribback S, Peters K, Ekin Demir I, Armbrecht N, Ceyhan GO, Manns MP, et al. Perioperative, spatiotemporally coordinated activation of T and NK cells prevents recurrence of pancreatic cancer. Cancer Res. 2017. canres.2415.017. doi:10.1158/0008-5472.Can-17-2415.
   Web of Science ®Google Scholar